Abstract

PreScription: First Estriol, Then What?

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2008 - Hormone Replacement Therapy

View All Articles in Issue

Page(s): 284

Download in electronic PDF format for $75

Abstract

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Jul/Aug 2008 Pg. 284	PreScription: First Estriol, Then What? Author(s): Allen Loyd V Jr
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
May/Jun 2006 Pg. 175-183	The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Jan/Feb 2019 Pg. 32-33	U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Jul/Aug 2008 Pg. 286-292	Estriol: Women's Choice vs. A Manufacturer's Greed Author(s): Goodrum Jennifer
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Jul/Aug 2007 Pg. 326-327	Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Author(s): Kupiec Tom, Kemp Jesse
Jan/Feb 2001 Pg. 52-54	Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Author(s): Ford Gina, Garcia Lea
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Jul/Aug 2003 Pg. 250-256	A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Author(s): Gillson George R, Zava David T
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Jan/Feb 2014 Pg. 35-36	U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Author(s): Miller David G
Nov/Dec 2020 Pg. 451-458	Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Author(s): Allen W Chris, Greeson Nicole MH, Mixon William
Sep/Oct 2023 Pg. 358-360	Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Author(s): Biundo Bruce